Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Protein engineering of a stable and potent anti-inflammatory IL-37-Fc fusion with enhanced therapeutic potential.
Bujotzek A, Tiefenthaler G, Lariviere L, D'Andrea L, Marquez EA, Rudloff I, Cho SX, Deen NS, Richter W, Regenass-Lechner F, Poehler A, Whisstock JC, Sydow-Andersen J, Reiser X, Schuster S, Neubauer J, Hoepfl S, Richter K, Nold MF, Nold-Petry CA, Schumacher F, Ellisdon AM. Bujotzek A, et al. Among authors: regenass lechner f. Cell Chem Biol. 2022 Apr 21;29(4):586-596.e4. doi: 10.1016/j.chembiol.2021.10.004. Epub 2021 Oct 25. Cell Chem Biol. 2022. PMID: 34699747 Free article.
Toll-Like Receptor 7 Agonist RG7854 Mediates Therapeutic Efficacy and Seroconversion in Woodchucks With Chronic Hepatitis B.
Wildum S, Korolowicz KE, Suresh M, Steiner G, Dai L, Li B, Yon C, De Vera Mudry MC, Regenass-Lechner F, Huang X, Hong X, Murreddu MG, Kallakury BV, Young JAT, Menne S. Wildum S, et al. Among authors: regenass lechner f. Front Immunol. 2022 May 23;13:884113. doi: 10.3389/fimmu.2022.884113. eCollection 2022. Front Immunol. 2022. PMID: 35677037 Free PMC article.
Development of a nonhuman primate challenge model to evaluate CD8+ T cell responses to an adenovirus-based vaccine expressing SIV proteins upon repeat-dose treatment with checkpoint inhibitors.
Graveline R, Haida M, Dumont C, Poulin D, Poitout-Belissent F, Samadfam R, Kronenberg S, Regenass-Lechner F, Prell R, Piche MS. Graveline R, et al. Among authors: regenass lechner f. MAbs. 2022 Jan-Dec;14(1):1979447. doi: 10.1080/19420862.2021.1979447. MAbs. 2022. PMID: 34923919 Free PMC article.
Current nonclinical approaches for immune assessments of immuno-oncology biotherapeutics.
Grimaldi C, Ibraghimov A, Kiessling A, Rattel B, Ji C, Fuller CL, Brennan FR, Regenass-Lechner F, Shenton J, Price KD, Piché MS, Steeves MA, Prell R, Dudal S, Kronenberg S, Freebern W, Blanset D. Grimaldi C, et al. Among authors: regenass lechner f. Drug Discov Today. 2023 Feb;28(2):103440. doi: 10.1016/j.drudis.2022.103440. Epub 2022 Nov 12. Drug Discov Today. 2023. PMID: 36375739 Free article. Review.